Details of the Drug

General Information of Drug (ID: DMNVFZA)

Drug Name
AC-1202
Synonyms Ketasyn
Indication
Disease Entry ICD 11 Status REF
Memory loss MB21.1Z Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 470.7
Logarithm of the Partition Coefficient (xlogp) 8.9
Rotatable Bond Count (rotbonds) 26
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 6
Chemical Identifiers
Formula
C27H50O6
IUPAC Name
2,3-di(octanoyloxy)propyl octanoate
Canonical SMILES
CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC
InChI
InChI=1S/C27H50O6/c1-4-7-10-13-16-19-25(28)31-22-24(33-27(30)21-18-15-12-9-6-3)23-32-26(29)20-17-14-11-8-5-2/h24H,4-23H2,1-3H3
InChIKey
VLPFTAMPNXLGLX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
10850
ChEBI ID
CHEBI:76978
CAS Number
538-23-8
UNII
6P92858988
DrugBank ID
DB12176
TTD ID
D01IHR

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ketogenesis (KG) TTNHYJL NOUNIPROTAC Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00142805) Ketasyn in Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
2 Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009 Aug 10;6:31.